Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/10/21
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung CancerGlobeNewsWire • 08/19/21
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/29/21
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5thGlobeNewsWire • 07/26/21
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory BoardGlobeNewsWire • 07/21/21
Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer TrialBenzinga • 06/04/21
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6thGlobeNewsWire • 04/30/21
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell CarcinomaGlobeNewsWire • 04/23/21
Blade Therapeutics Announces Appointment of Jean-Frédéric Viret as Chief Financial OfficerBusiness Wire • 03/22/21
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/24/21
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 02/24/21
Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to DeclineZacks Investment Research • 02/18/21
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for ReviewGlobeNewsWire • 02/17/21